Bio­haven's re­for­mu­lat­ed ALS drug is a flop in anx­i­ety, un­nerv­ing in­vestors ahead of CGRP mi­graine de­ci­sion

4 years ago
R&D

FDA hands Gilead a nice CAR-T boost as crit­ics pounce on un­der­whelm­ing Q4 call and Twit­ter buzzes with M&A chat­ter

4 years ago
R&D

Fo­cus­ing on ge­net­i­cal­ly de­fined pop­u­la­tion still could­n't save Eli Lil­ly, Roche's an­ti-amy­loid Alzheimer's drugs

4 years ago
R&D

A crash­ing Wave takes out the bud­get ax to chop staff, aban­don­ing work on Duchenne MD in re­struc­tur­ing

4 years ago
People
R&D

Craig Bas­son tells us why he leapt from NI­BR to Boston Phar­ma; Ex-BMS Part­ner Cy­tomX finds new CMO in Al­li­son Han­nah

4 years ago
Peer Review

Kym­ri­ah pi­o­neer Carl June is back, with first US hu­man ev­i­dence for CRISPR use in can­cer

4 years ago
Cell/Gene Tx

Scott Got­tlieb adds one more high-pro­file board seat to the post-FDA re­sume. And it’s an­oth­er plum as­sign­ment

4 years ago
People

Par­ty on: Base edit­ing start­up, com­pu­ta­tion­al drug dis­cov­ery ex­perts and CRO bag close to $2B to­tal on their way to Nas­daq

4 years ago
Financing

GSK’s vac­cines group — in­clud­ing R&D — faces heavy job cuts in lat­est re­struc­tur­ing

4 years ago
R&D

Jef­frey Blue­stone ex­its Park­er and switch­es fo­cus back to au­toim­mune dis­eases in cell ther­a­py 2.0 launch

4 years ago
R&D

Sanofi's R&D group spot­lights a big win for BT­Ki mul­ti­ple scle­ro­sis drug. But plen­ty of ques­tions re­main

4 years ago
R&D

Bio­gen shares rock­et up as My­lan's chal­lenge to Tec­fidera patents is slapped down

4 years ago
Pharma

It's not just about Keytru­da, Mer­ck in­sists, as it carves out as­sets worth $6.5B in­to new com­pa­ny

4 years ago
Deals
R&D

Glax­o­SmithK­line's lat­est makeover in­cludes auc­tion­ing off der­ma­tol­ogy, adding new tech and lay­offs. But how many?

4 years ago
R&D

Yes, Gilead CEO Daniel O’Day is ready to ink some deals. No, you won’t see him sweat it

4 years ago
Bioregnum
R&D

Bio­Mo­tiv, Bris­tol-My­ers al­liance bears fruit with new com­pa­ny: An­teros Phar­ma

4 years ago
Deals
R&D

Q&A with Jorge Conde as An­dreessen Horowitz launch­es $750M bio fund III

4 years ago
Financing

In­smed’s PhII smokes and sput­ters, but re­searchers her­ald enough sur­pris­ing­ly pos­i­tive da­ta to roar on Wall Street

4 years ago
R&D

Unit­ed Ther­a­peu­tic­s' drug fails PhII/III can­cer tri­al, mark­ing their sec­ond straight stum­ble in post-Re­mod­ulin PAH

4 years ago
R&D

Roche vet San­dra Horn­ing jumps on bio­phar­ma board no. 3 — what’s that worth?

4 years ago
R&D

Catal­ent chief John Chimin­s­ki trig­gers a $315M-plus wa­ger on the boom­ing cell ther­a­py mar­ket now in the mak­ing

4 years ago
Deals
Outsourcing

Gilead surges wild­ly as world scram­bles to counter a like­ly coro­n­avirus pan­dem­ic while GSK pitch­es in on vac­cine R&D cam­paign

4 years ago
Pharma
Coronavirus

Biotech was big in 2019, but here's one record no one want­ed to see bro­ken: Most bank­rupt­cies

4 years ago
Pharma

Mod­er­na woos tri­al vet Melanie Ivars­son to the se­nior R&D team; Ex-Roche CMO San­dra Horn­ing joins Gilead board

4 years ago
Peer Review
First page Previous page 181182183184185186187 Next page Last page